Norvir, Ritonavir News

The risk and course of serum transaminase elevations and clinical hepatic serious adverse event development in ritonavir-boosted tipranavir 500/200mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials , was determined.

Revised U.S. Antiretroviral Therapy Guidelines Call for Earlier Treatment and Promote Raltegravir to a Preferred First-line Option SUMMARY: On December 1, the U.S. Department of Health and Human Services updated its guidelines for antiretroviral therapy for HIV positive adults and adolescents.

SUMMARY: On World AIDS Day, Tibotec Therapeutics launched a new program to provide information about issues facing HIV positive women and people of color receiving antiretroviral therapy.

Paul E. Sax, M.D., Camlin Tierney, Ph.D., Ann C. Collier, M.D., Margaret A. Fischl, M.D., Katie Mollan, M.S., Lynne Peeples, M.S., Catherine Godfrey, M.D., Nasreen C. Jahed, M.P.H., Laurie Myers, M.S., David Katzenstein, M.D., Awny Farajallah, M.D., James F. Rooney, M.D., Belinda Ha, Ph.D., William C. Woodward, M.D., Susan L. Koletar, M.D., ...

Boosted Darunavir Monotherapy Works Well as Maintenance Therapy, but Not So Well as Initial Regimen SUMMARY: Protease inhibitor monotherapy using ritonavir-boosted darunavir was able to keep HIV suppressed when used as a simplified maintenance regimen in patients who achieved undetectable viral load on combination antiretroviral therapy , according ...

An entire session at the 12th European AIDS Conference was devoted to trials of different ritonavir-boosted protease inhibitors used as the sole drug in an antiretroviral regimen.

Main Category: HIV / AIDS Also Included In: Clinical Trials / Drug Trials Article Date: 11 Nov 2009 Concert Pharmaceuticals, Inc.

SUMMARY: In the NEXT-1 study, presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston, the experimental HCV NS3 protease inhibitor narlaprevir , boosted with ritonavir , demonstrated potent antiviral activity in combination with pegylated interferon and ribavirin among treatment-naive ...

SUMMARY: It may be possible to use certain HIV protease inhibitors with lower boosting doses of ritonavir, according to an article published in the November 13, 2009 issue of the journal AIDS .

According to the most recent report from the Centers for Disease Control and Prevention, more than one million people are living with HIV and the annual incidence of new infections was 56,300 in the U.S.1 It is critical that effective and tolerable medicines are available to patients initiating antiretroviral therapy.

Raltegravir , Etravirine , and Boosted Darunavir Is Effective for Heavily Treatment-experienced Patients SUMMARY: A regimen of raltegravir , etravirine , and ritonavir-boosted darunavir was well tolerated and produced high rates of virological suppression in heavily treatment-experienced HIV patients with extensively drug-resistant virus, according ...

A combination of darunavir/ritonavir, etravirine, and raltegravir is 'remarkably' effective in HIV-positive adolescents with extensive prior experience of antiretroviral therapy, French investigators report in the November 13th edition of AIDS .

A combination of raltegravir, etravirine and darunavir/ritonavir is highly effective at suppressing viral load to undetectable levels in treatment-experienced patients, French investigators report in the November 1st edition of Clinical Infectious Diseases .

The standard dose of the antibiotic rifabutin, used in the treatment of tuberculosis and other mycobacterial infections, is probably inadequate when used alongside the protease inhibitor Kaletra , US researchers report in the November 1st edition of Clinical Infectious Diseases.

The amount of ritonavir needed to boost levels of other protease inhibitors differs between individual drugs, a meta-analysis published in the online edition of AIDS suggests.

First-line antiretroviral therapy that includes a nucleoside/nucleotide backbone of tenofovir/emtricitabine was more effective than regimens containing abacavir/lamivudine for HIV patients with high pre-treatment viral load, according to a meta-analysis published in the October 2009 issue of HIV Medicine .

Raltegravir , Etravirine , and Ritonavir-boosted Darunavir Is a Safe and Successful Salvage Regimen A combination of the integrase inhibitor raltegravir , the non-nucleoside reverse transcriptase inhibitor etravirine , and the ritonavir-boosted protease inhibitor darunavir was well-tolerated and highly effective as a "salvage" antiretroviral ...

InterMune, Inc. today announced that its partner Roche has begun dosing in a Phase 1b multiple ascending dose study of ITMN-191 boosted by low-dose ritonavir in patients chronically infected with hepatitis C virus genotype-1. Ritonavir boosting is an option to enhance and improve pharmacokinetic profiles of protease inhibitors.

Investigational Pharmaco-enhancer GS-9350 Equals Ritonavir as a Booster for Atazanavir Boosting agents work by interfering with enzymes in the liver that process other drugs.

Nevirapine and Boosted Atazanavir Produce Comparable Early Virological and Immunological Response Early virological response has been proposed as a marker of efficacy of antiretroviral therapy .